{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:31:25Z","timestamp":1793043085721,"version":"4.5.0"},"reference-count":27,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Janssen Pharmaceuticals, K.K. Japan"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Early diagnosis of primary or light chain (AL) amyloidosis is crucial for initiating appropriate therapeutic interventions. However, diagnosis is getting delayed (several months-to-years) in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To investigate the real-world patterns of clinical procedures until initial diagnosis of AL amyloidosis in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective longitudinal, observational cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study included adults with AL amyloidosis using Medical Data Vision claims database (2003\u20132022). The primary endpoint was time from initial hospital visit until confirmed AL amyloidosis diagnosis. Symptoms, lab tests, and medical department visits until diagnosis, and mortality were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Overall, 323 patients with AL amyloidosis were included (median age: 73.0\u2009years). Median time to confirmed diagnosis was 81.5\u2009days; reported longer in patients aged \u2a7e65\u2009years versus &lt;65\u2009years, and Charlson Comorbidity Index \u2a7e4 than &lt;4. Specific tests (tissue and bone marrow biopsy) were conducted 28\u201340\u2009days close to the diagnosis. Patients visited internal medicine (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009158), hematology medicine (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009139), dermatology (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200997), and nephrology (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200993) departments for confirmed diagnosis. Time to confirmed diagnosis was shorter for patients who visited hematology (median: 7.5\u2009days). Early diagnosed (\u2a7d1\u2009year) patients had longer time-to-in-hospital death than late diagnosis (&gt;1\u2009year).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These real-world data from Japanese AL amyloidosis patients are crucial for early and effective treatment, leading to better prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207251379852","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:12:37Z","timestamp":1771845157000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["A retrospective real-world study assessing diagnostic pattern of light-chain amyloidosis in Japan based on data from the medical data vision claims database"],"prefix":"10.1177","volume":"17","author":[{"given":"Moe","family":"Yogo","sequence":"first","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0170-1442","authenticated-orcid":false,"given":"Mami","family":"Kasahara-Kiritani","sequence":"additional","affiliation":[{"name":"Integrated Market Access Division, Johnson &amp; Johnson, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Oshima","sequence":"additional","affiliation":[{"name":"Medical Affairs Division, Johnson &amp; Johnson, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya-ku, Tokyo 150-8935, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.14797\/mdcvj.1070"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02414-6"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/ncn3.12384"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00396"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00483-7"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.08.009"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9206-17"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27177"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13679"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.944503"},{"key":"e_1_3_4_12_2","unstructured":"Medical Data Vision (MDV). Learning the most from Japanese Medical Data by using one of the largest database https:\/\/en.mdv.co.jp\/ (2024 accessed May 2025)."},{"key":"e_1_3_4_13_2","unstructured":"Medical Data Vision (MDV) EBM insight. MDV database overview https:\/\/en.mdv.co.jp\/ebm\/about-mdv-database\/mdv-database-overview\/ (2024 accessed May 2025)."},{"key":"e_1_3_4_14_2","unstructured":"Ministry of Health Law. Appendix 1 E-20: Department classification (Ministry of Health Labor and Welfare Form Code Table) 138 https:\/\/www.mhlw.go.jp\/topics\/2009\/05\/dl\/tp0521-1a_0053.pdf (2009 accessed May 2025)."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_4_16_2","unstructured":"von Elm E Altman DG Egger M et al. The STROBE reporting checklist. In: Harwood J Albury C de Beyer J et al. (eds) The EQUATOR network reporting guideline platform [Internet]. The UK EQUATOR Centre 2025 https:\/\/resources.equator-network.org\/reporting-guidelines\/strobe\/strobe-checklist.docx."},{"key":"e_1_3_4_17_2","unstructured":"Social Insurance Medical Fee Payment Fund. [Tests] 83. Billing for hematopoietic tumor cell antigen tests https:\/\/www.ssk.or.jp\/shinryohoshu\/sinsa_jirei\/kikin_shinsa_atukai\/shinsa_atukai_i\/kensa_1.files\/kensa_19.pdf (2024 accessed May 2025)."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01040-8"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-017-0273-5"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2137400"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2017.1411796"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.128025"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-18990-3"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13156"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013354"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.07.007"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13681"},{"key":"e_1_3_4_28_2","unstructured":"Ministry of Health Law. Ethical guidelines for life science and medical research involving human subjects (main text) (partially revised on March 27 2023) https:\/\/www.mhlw.go.jp\/content\/001077424.pdf. (2023 accessed June 2025)."}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251379852","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207251379852","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251379852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:17:57Z","timestamp":1777591077000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207251379852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"alternative-id":["10.1177\/20406207251379852"],"URL":"https:\/\/doi.org\/10.1177\/20406207251379852","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"20406207251379852"}}